Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership on 09/01/2025. He received 264 restricted stock units that vested (reported as 264 shares acquired at $0), increasing his holdings to 45,087 shares. On the same date he disposed of 139 shares at a reported price of $67.42, leaving 44,948 shares beneficially owned after the transactions. The disclosure notes the RSU award was granted on November 2, 2021, with an initial 25% vesting on September 1, 2022, and the remaining 75% vesting quarterly over the following three years.
Guardant Health director and Chief Information Officer Kumud Kalia reported transactions on Form 4 showing restricted stock units vesting and a small open-market sale. On 09/01/2025, 711 shares were reported as acquired at a $0 price reflecting the vesting of RSUs, leaving 19,211 shares beneficially owned. The filing also shows a disposal of 361 shares on 09/01/2025 at a price of $67.42, reducing reported holdings to 18,850 shares. The RSU award was originally granted in November 2021 and vests quarterly through the three-year schedule that began 09/01/2022.
Darya Chudova, identified as Chief Technology Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership on a Form 4 filed for transactions dated 09/01/2025. The filing shows 316 restricted stock units deemed acquired at $0 (coded M) related to RSU vesting, and a reported disposition of 161 shares at $67.42. Following the transactions, the reporting person is shown as beneficially owning 81,610 shares after the acquisition line and 81,449 after the disposition line. The RSU award was originally granted on November 2, 2021 and fully vests on September 1, 2025, with vesting occurring in equal quarterly installments.
Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported acquisitions on Form 4 dated 08/31/2025. The filing shows a non-derivative entry and a derivative entry reflecting restricted stock units. The non-derivative entry records 155 shares acquired on 08/31/2025 at an aggregate price of $0, bringing his direct beneficial ownership of common stock to 18,128 shares. The derivative section shows 155 restricted stock units reported on 08/31/2025 with a $0 price, corresponding to 1,543 shares of common stock beneficially owned following the transaction on a direct basis. Explanatory notes state the RSU award was granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the following three years.
This Form 144 notice records a proposed sale of 100 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., with an aggregate market value of $6,584 and an approximate sale date of 09/02/2025. The filer reports acquiring the shares through restricted stock lapses: 34 shares on 06/12/2025 and 66 shares on 07/04/2025, both listed as equity compensation.
The filing also discloses sales by the same person within the past three months: 100 shares sold on 06/02/2025 for $4,166 and 3,337 shares sold on 06/13/2025 for $157,573. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
Kumud Kalia, Chief Information Officer of Guardant Health (GH), reported a sale of 2,000 shares of the company's common stock on 08/21/2025 at a reported price of $61.755 per share. After this transaction the filing shows 18,500 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact on 08/22/2025 and discloses the officer role and timely reporting of the change in ownership.
Guardant Health, Inc. (GH) Form 144 shows a proposed Rule 144 sale and recent related transactions by insiders. The filer reports intent to sell 2,000 common shares through Charles Schwab with an aggregate market value of $123,510 and an approximate sale date of 08/21/2025 on NASDAQ. Those 2,000 shares were acquired on 10/01/2024 via the lapse of restricted stock as equity compensation. The filing also discloses a prior sale by Kumud Kalia of 4,000 shares on 06/03/2025 for gross proceeds of $185,562. The notice includes the standard insider representation regarding material undisclosed information and potential 10b5-1 plan disclosure.
Director Tariq Musa reported a sale of Guardant Health (GH) common stock. On 08/19/2025 Mr. Musa sold 116 shares at $59.02 per share, leaving him with 7,458 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 08/20/2025 and indicates the transaction was a sale by the reporting person.
Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported an open-market sale of 26 shares of the company's common stock on 08/19/2025 at a price of $59.02 per share. After the reported transaction, Potter beneficially owned 18,239 shares. The Form 4 indicates the filing was executed by an attorney-in-fact and filed on 08/20/2025. The form is marked as a sale pursuant to a written plan under Rule 10b5-1.
Form 144 notice for Guardant Health, Inc. (GH) reporting a proposed sale of 116 common shares through Charles Schwab & Co., Inc. on 08/19/2025 with an aggregate market value of $6,846.00. The shares were acquired on 08/15/2025 via a restricted stock lapse from Guardant Health and the payment/nature is listed as equity compensation. The filer or seller identified in prior transactions is Musa Tariq, who sold shares on 05/19/2025 (116 shares, $4,645.00), 06/18/2025 (3,213 shares, $158,947.00), and 07/17/2025 (116 shares, $5,591.00). The form includes the standard representation that the seller has no undisclosed material adverse information.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
